Vasoplegia syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vasoplegia syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Early Treatment with Argipressin (Arginine Vasopressin) in Adult Intensive Care Patients with Norepinephrine-Resistant Vasoplegic Shock https://clinicaltrials.eu/trial/early-treatment-with-argipressin-arginine-vasopressin-in-adult-intensive-care-patients-with-norepinephrine-resistant-vasoplegic-shock/ Wed, 29 Apr 2026 15:06:23 +0000 https://clinicaltrials.eu/trial/early-treatment-with-argipressin-arginine-vasopressin-in-adult-intensive-care-patients-with-norepinephrine-resistant-vasoplegic-shock/ This study focuses on patients with norepinephrine-refractory vasoplegic shock, a severe condition where blood vessels become abnormally dilated, leading to dangerously low blood pressure that does not respond adequately to standard treatment with norepinephrine. The study will test a medication called Reverpleg (also known as argipressin or arginine vasopressin), which is given through an intravenous infusion.

The purpose of this research is to determine if early treatment with Reverpleg can improve outcomes compared to placebo in patients with this type of shock. During the study, patients will receive either Reverpleg or placebo through an intravenous line for up to 7 days. They will also receive standard medical care, including a solution of sodium chloride for fluid replacement.

The study will monitor various aspects of patient recovery, including survival, kidney function, and how long patients need medication to maintain their blood pressure. Patients will be followed for up to 90 days to assess their recovery and any potential side effects of the treatment.

]]> Study Comparing Vasopressin and Noradrenaline for Patients with Vasoplegic Syndrome Undergoing Cardiac Surgery with Extracorporeal Circulation https://clinicaltrials.eu/trial/study-comparing-vasopressin-and-noradrenaline-for-patients-with-vasoplegic-syndrome-undergoing-cardiac-surgery-with-extracorporeal-circulation/ Wed, 29 Apr 2026 14:25:15 +0000 https://clinicaltrials.eu/trial/study-comparing-vasopressin-and-noradrenaline-for-patients-with-vasoplegic-syndrome-undergoing-cardiac-surgery-with-extracorporeal-circulation/ This clinical trial is focused on studying a condition known as vasoplegic syndrome, which can occur in patients undergoing heart surgery with the help of a machine that temporarily takes over the function of the heart and lungs, known as extracorporeal circulation. The study aims to compare two different treatments to manage blood pressure in these patients: Vasopressin and Norepinephrine. Vasopressin, also known by its code name REVERPLEG, is a medication that helps to increase blood pressure by narrowing blood vessels. Norepinephrine, also known as Noradrenaline, works similarly by tightening blood vessels to raise blood pressure.

The purpose of this study is to determine which of these two medications is more effective in preventing kidney problems and death within seven days after the onset of vasoplegic syndrome in patients undergoing heart surgery. Participants in the study will receive either Vasopressin or Norepinephrine through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will monitor participants for any kidney complications or other health issues for up to 90 days after the onset of vasoplegic syndrome. This includes checking for heart problems, digestive issues, and brain-related complications. The study will also look at the overall costs and effectiveness of the treatments, including how long patients stay in the hospital and the costs associated with their care. The goal is to find the best strategy to manage blood pressure and improve outcomes for patients at risk of kidney problems during heart surgery.

]]>